Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b
Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t